Pharmaceutical News

RSS

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

The Drugs for Neglected Diseases initiative, based in Geneva, Switzerland, and DNDi Japan, based in Tokyo, welcome the launch of the Global Health Innovative Technology Fund, an initiative supported by the Japanese government, several Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation.

9 Apr 2013

Research findings could help develop effective vaccines against new strains of bird flu

Scientists have described small genetic changes that enable the H5N1 bird flu virus to replicate more easily in the noses of mammals.

9 Apr 2013

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

New national study examines marijuana use and prescription drug misuse

Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to a new national study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services.

From Quest Diagnostics 9 Apr 2013

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

9 Apr 2013

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.

9 Apr 2013

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Genzyme, a Sanofi company, announced today Argentina's National Administration of Drugs, Food and Medical Technology has approved once-daily, oral AUBAGIO 14 mg as a new treatment indicated for patients with relapsing forms of multiple sclerosis.

9 Apr 2013

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

The U.S. Food and Drug Administration today approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) to treat pregnant women experiencing nausea and vomiting.

9 Apr 2013

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Nearly half of the world's population is at risk of infection by the dengue virus, yet there is no specific treatment for the disease. Now a therapy to protect people from the virus could finally be a step closer, thanks to a team at MIT.

9 Apr 2013

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

Gilead Sciences today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection.

9 Apr 2013

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Medications to treat arrhythmias may increase the risk of developing cancer

One of the most widely used medications to treat arrhythmias may increase the risk of developing cancer, especially in men and people exposed to high amounts of the drug.

8 Apr 2013

Research: HIV women infected with HPV are not protected by current vaccines

Women with HIV acquire cancer-causing forms of the human papillomavirus (HPV) that are not included in the current HPV vaccines Gardasil and Cervarix, according to new research from Fox Chase Cancer Center being presented at the AACR Annual Meeting 2013 on Sunday, April 7.

8 Apr 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).

8 Apr 2013

Neutra executive leadership to meet with California's medical marijuana experts

Neutra Corp., a provider of all-natural wellness solutions, announced today that its executive leadership will travel to California next week to meet with veteran experts on that state's medical marijuana industry.

8 Apr 2013

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

Bayer HealthCare announced today that the New Drug Application for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration for the treatment of inoperable chronic thromboembolic pulmonary hypertension or with persistent or recurrent CTEPH after pulmonary endarterectomy and pulmonary arterial hypertension.

8 Apr 2013

New two-step immunotherapy approach offers new hope for ovarian cancer patients

As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach -- including one patient who achieved complete remission -- according research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today in a press conference at the AACR Annual Meeting 2013 (Presentation #LB-335).

8 Apr 2013

National Jewish Health researchers unravel mystery of adjuvants

Aluminum salts, or alum, have been injected into billions of people as an adjuvant to make vaccines more effective.

8 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013

First Korean/U.S. workshop on drug regulation and marketing

Getting more and better drugs to market for patients was the ultimate goal of the University of Maryland School of Pharmacy's first Korean/U.S. workshop on drug regulation and marketing from March 18 to 22.

6 Apr 2013

Pharmaceutical News

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

Research findings could help develop effective vaccines against new strains of bird flu

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

New national study examines marijuana use and prescription drug misuse

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Diclegis gets FDA approval for treatment of nausea and vomiting of pregnancy

MIT researchers present novel approach to develop dengue therapy using mutated antibodies

Gilead Sciences submits sofosbuvir NDA to FDA for treatment of chronic HCV infection

New drug combination shows anti-cancer activity in patients with solid tumors and germline mutation

Medications to treat arrhythmias may increase the risk of developing cancer

Research: HIV women infected with HPV are not protected by current vaccines

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Neutra executive leadership to meet with California's medical marijuana experts

FDA grants priority review for Bayer HealthCare's riociguat for treatment of CTEPH

New two-step immunotherapy approach offers new hope for ovarian cancer patients

National Jewish Health researchers unravel mystery of adjuvants

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

First Korean/U.S. workshop on drug regulation and marketing

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News